Advancing Science. Improving Connections.

Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.

Our People

Focusing on the unmet medical needs of patients with rare disorders and their families


Our Company

Progressing our mission to improve the lives of patients battling certain rare conditions


Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions


Latest News


Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Read More

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

Read More

Zynerba Pharmaceuticals Presents Data on Zygelâ„¢ at the 55th Gatlinburg Conference

Read More

Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

Read More

You are now leaving the Zynerba website

You are being redirectd to a third-party website. The terms and conditions of this third-party website may be different from and will govern your use of such website.

Continue (5) Cancel